RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
XSpray Pharma AB (publ) Stock

XSpray Pharma AB (publ) P/E 2025

XSpray Pharma AB (publ) P/E

-23.86

Ticker

XSPRAY.ST

ISIN

SE0009973563

WKN

A2H48J

As of Jan 8, 2025, XSpray Pharma AB (publ)'s P/E ratio was -23.86, a 135.07% change from the -10.15 P/E ratio recorded in the previous year.

The XSpray Pharma AB (publ) P/E history

XSpray Pharma AB (publ) Aktienanalyse

What does XSpray Pharma AB (publ) do?

XSpray Pharma AB (publ) was founded in Sweden in 2003 and is headquartered in Stockholm. The company specializes in the development and manufacturing of pharmaceutical products tailored to the needs of patients with unique medical challenges. The business model of XSpray Pharma is based on patenting and selling its MicroSpray technology platform, which allows drugs to be transformed into a microfine spray form, thereby improving bioavailability, duration, and intensity of action. The company has three main divisions: - The first division is contract research, where XSpray Pharma licenses its technology platform to other pharmaceutical companies and assists them in drug development. - The second division is the development of its own medications, where XSpray Pharma develops innovative therapies for rare diseases. The company works closely with patient organizations, doctors, and scientists to better understand patient needs and address their medical challenges. - The third division is partnership with other pharmaceutical companies, where XSpray Pharma contributes its technology platform and drug development expertise to collaboratively develop and market innovative therapies. One of XSpray Pharma's key products is APT-1011, a spray for severe nausea and vomiting in cancer patients that acts quickly and effectively due to its microfine nature. It has received European approval (EMA) and is being submitted in the US in collaboration with US pharmaceutical company RedHill Biopharma. Another important product is APT-1026, a spray for the treatment of hypersensitivity reactions. It is currently in development and is intended to help patients with various types of hypersensitivity reactions in the future. In addition, XSpray Pharma has several patented technology platforms and a wide range of drug candidates in the pipeline. The company works closely with its partners to leverage its technology and expertise in drug development to jointly create innovative therapies for patients. In recent years, XSpray Pharma has received several awards and recognitions for its innovative technology and drug development, including the Swedish Pharma Prize and the European Mediscience Award. In summary, XSpray Pharma is an innovative pharmaceutical company specializing in the development of drugs for patients with unique medical challenges. The company has utilized its MicroSpray technology platform and drug development expertise to develop a wide range of drug candidates in the pipeline aimed at improving the lives of patients. XSpray Pharma AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering XSpray Pharma AB (publ)'s P/E Ratio

The Price to Earnings (P/E) Ratio of XSpray Pharma AB (publ) is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing XSpray Pharma AB (publ)'s P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of XSpray Pharma AB (publ) is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in XSpray Pharma AB (publ)’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about XSpray Pharma AB (publ) stock

What is the price-to-earnings ratio of XSpray Pharma AB (publ)?

The price-earnings ratio of XSpray Pharma AB (publ) is currently -23.86.

How has the price-earnings ratio of XSpray Pharma AB (publ) changed compared to last year?

The price-to-earnings ratio of XSpray Pharma AB (publ) has increased by 135.07% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of XSpray Pharma AB (publ) high compared to other companies?

Yes, the price-to-earnings ratio of XSpray Pharma AB (publ) is high compared to other companies.

How does an increase in the price-earnings ratio of XSpray Pharma AB (publ) affect the company?

An increase in the price-earnings ratio of XSpray Pharma AB (publ) would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of XSpray Pharma AB (publ) affect the company?

A decrease in the price-earnings ratio of XSpray Pharma AB (publ) would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of XSpray Pharma AB (publ)?

Some factors that influence the price-earnings ratio of XSpray Pharma AB (publ) are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does XSpray Pharma AB (publ) pay?

Over the past 12 months, XSpray Pharma AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XSpray Pharma AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of XSpray Pharma AB (publ)?

The current dividend yield of XSpray Pharma AB (publ) is .

When does XSpray Pharma AB (publ) pay dividends?

XSpray Pharma AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XSpray Pharma AB (publ)?

XSpray Pharma AB (publ) paid dividends every year for the past 0 years.

What is the dividend of XSpray Pharma AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is XSpray Pharma AB (publ) located?

XSpray Pharma AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von XSpray Pharma AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XSpray Pharma AB (publ) from 1/8/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did XSpray Pharma AB (publ) pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of XSpray Pharma AB (publ) in the year 2024?

In the year 2024, XSpray Pharma AB (publ) distributed 0 SEK as dividends.

In which currency does XSpray Pharma AB (publ) pay out the dividend?

The dividends of XSpray Pharma AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von XSpray Pharma AB (publ)

Our stock analysis for XSpray Pharma AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XSpray Pharma AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.